Pharmaceutical

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Sep 20, 2024 - 04:00
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.
Read the original article

Tags:

Previous Article

Biotechs investigate ways to adapt to new clinical trial regulation and economic...

Next Article

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

BMS and Prime ink potential $3.5bn deal to develop T ce...

Oct 2, 2024

Opinion: BMI as a barrier to orthopedic surgery doesn’t make sense for patient health

Opinion: BMI as a barrier to orthopedic surgery doesn’t...

Jan 16, 2024

Eli Lilly doubles down on Oblique partnership for antibody generation

Eli Lilly doubles down on Oblique partnership for antib...

Aug 25, 2024